Research programme: cancer diagnostic and therapeutic agents - Kereos

Drug Profile

Research programme: cancer diagnostic and therapeutic agents - Kereos

Alternative Names: KER 0001; KER 1001; KER 1002; KER 1003; KI 001; KI-0001; KI-0003; KI-1001; KI-1003 - Kereos; KI-100X; Melittin nanoparticles - Kereos; Mellitin nanoparticles - Kereos; Nanobees - Kereos

Latest Information Update: 27 Nov 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Washington University School of Medicine
  • Developer Kereos
  • Class Diagnostic agents; Pore forming cytotoxic proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 26 Nov 2015 Preclinical development is ongoing for diagnosis and treatment of Solid tumours in USA
  • 29 May 2007 Preclinical development is ongoing
  • 01 Jul 2004 The programme is available for licensing (http://www.kereos.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top